These delayed, and much expanded, guidelines for the management of hypertension, represent the third attempt by the British Hypertension Society (BSH) to influence clinical practice. 1 There will be many who feel that the 6-year gap between these guidelines and those based on the Second Working Party in 1993 has been too long. However, one major consequence is the sheer weight of strong clinical evidence that permeates throughout these guidelines, some of which was published quite recently such as important data to guide appropriate targets for blood pressure treatment. 2, 3 The result makes for very compelling reading.
Although the guidelines have also been published in summary form in the British Medical Journal, 4 I hope that most doctors will take the time to read the full guidelines published in this journal. However, at over 16 pages of close type-face, it seems likely that few practitioners will avail themselves of this reasonable, and reasonably concise, summary of the best evidence available that has been categorised by the authors. My hope, and recommendation, would be that, at the very least, the clinical governance leads for primary care groups around the country and whoever leads on coronary heart disease within individual practices will indeed read and digest the content of these revised guidelines. They could do a lot worse than use these as the basis for their approach to cardiovascular risk reduction.
Not surprisingly, it will become apparent that one major issue for these guidelines is to avoid the viewpoint that hypertension is a disease in isolation. The importance of viewing hypertension alongside, and as part of the reduction of cardiovascular risk, is a major and repeated component. Fortunately, the authors have chosen to advocate for the formal estimation of 10-year coronary heart disease and cardiovascular disease risk using the methods advocated by the Joint British Societies. 5 The main practical 'drawback' of the joint British Society Coronary Risk calculations, unlike those of the European Joint Societies, is the requirement for estimation of highdensity lipoprotein (HDL) cholesterol. The authors of the BHS guidelines acknowledge the limited access some doctors have to this test by advocating the calculation of a HDL over total cholesterol ratio by assuming the level of HDL is 1 mmol per litre where accurate estimation is not possible. Such pragmatic recommendations appear occasionally within the article and are likely to be of considerable benefit to the busy clinician. Furthermore, such 'clinician friendly' practical interpretation of evidence is supported by non-judgmental text. For example the current under-performance of British general practice in adherence to blood pressure control targets is presented neutrally without quoting the bottom-line rates (such as only 6% of adult hypertensives achieving blood pressures below the Hypertension Optimal Treatment (HOT) study targets in the last Health Survey for England). 6 So what else is new and important in the guidelines? The first is that recommendations made throughout the text are graded according to the reliability of the information (A most reliable to D the least.) A second major factor is the highlighting of the importance of systolic blood pressure, particularly in elderly patients. Indeed, it is surprising that the perceived importance of diastolic pressure has remained intact for so long, given the closer epidemiological association between systolic blood pressure and major cardiovascular events. 7, 8 Very importantly for GPs, the guidelines also emphasis the necessity for differentiating thresholds for the diagnosis of hypertension and targets for the efficacy of treatment. The importance of differentiating, and adhering, to both threshold and targets cannot be overstated. Unfortunately, herein arguably lies the guidelines' principal problem-they are somewhat complicated in detail.
The authors can hardly be blamed for this since the treatment of hypertension and cardiovascular risk has moved on so far in the last few years. We now have a much better understanding of what levels of blood pressure are tolerable in what groups of patients and what treatment targets are most desirable between groups. Thus, there are differentiational guidelines between patients who are at most high risk, namely those who have already suffered a cardiovascular event such as heart attack; patients with diabetes, who should be considered as if they have already suffered an event; and patients who have not yet established disease but are at higher risk through a combination of adverse risk factors and/or isolated hypertension. The guidelines therefore recommend treatment thresholds dependent on which level of risk individual patients are exposed to. These explicit target levels are usefully duplicated in a simple algorithm.
These are all sensible and indeed manageable approaches to treating patients with hypertension and raised cardiovascular risk. But what are the implications for service providers? I believe the complexity needed to accurately differentiate patients on the basis of their risk and subsequently (and aggressively) manage their hypertension and associated risk factors effectively precludes the modern management of these patients within routine consultations. It is conceivable that, with adequate IT support at the point of consultation and 15-min appointments, a highly organised practitioner could achieve accurate risk stratification and patient follow-up within regular clinics. However, for the generality of practices, the implications of these guidelines are that hypertension can no longer be considered as part of routine clinical practice and should be managed as part of a structured package of care.
So what do the guidelines recommend should be incorporated into the care of hypertensives? I have mentioned the first very important, but often neglected, point reinforced in the guidelines of the importance of treating systolic as well as diastolic blood pressures.
Secondly, the guidelines make more substantive recommendations about ambulatory blood pressure monitoring (ABPM) than earlier versions. They helpfully summarise suggested target blood pressures for treatment for both using clinical BP and mean daytime ambulatory blood pressure measurement (average 24-h blood pressure measurements are not recommended). However, the authors express a number of reasonable concerns about the adoption of ABPM data, resulting in some rather complicated recommendations in which circumstances it is most appropriate to use ABPM rather than clinic measurements.
To the credit of the authors, their management section begins with an extensive review of nonpharmacological measures in both primary prevention of hypertension and its treatment. This section represents one of the major plus points of the new guidelines with as good a brief summary of the evidence for non-pharmacological interventions as I have come across. This section will make particularly valuable reading for primary care groups who might be considering developing patient information leaflets for hypertensives.
The third substantive area covered by the authors in terms of care packages, relates to appropriate thresholds for treating hypertension and subsequent treatment goals. As indicated earlier, the authors advocate the calculation of absolute coronary heart disease and cardiovascular disease risk on the basis of the combined British Societies' coronary risk prediction chart (or computer disc). Importantly, the authors reinforce the importance of assessing cardiovascular (CVS) risk as opposed to coronary heart disease (CHD) risk in isolation; CVS risk being easily estimated from CHD risk by multiplying the latter by 1.33 (or divide by 3 and multiply by 4). The section on thresholds for intervention, arguably, contain the most substantive changes to the new guidelines. Patients with blood pressures between 160-199 over 100-109 mm Hg should all be treated, assuming blood pressure persists after 4 -12 weeks of non-pharmacological advice (or immediately in the case of established cardiovascular disease and/or organ damage). The most important change relates to how doctors should decide when to treat mild hypertension, which would latterly have been described as borderline hypertension. Thus for blood pressures of 140-159 over 90-99 mm Hg, treatment should be instigated in the case of endorgan damage or established cardiovascular disease. Furthermore, in all such patients, absolute cardiovascular risk should be assessed to guide treatment of hypertension in much the same way, as clinicians will be using such risk calculations to guide the need for statin therapies. In the case of hypertension, the trigger for antihypertensive treatment in mild hypertension is suggested to be an estimated 10 years CHD risk of greater than 15% (or 20% cardiovascular risk).
Not surprisingly, treatment goals are dictated by the evidence from the HOT trial. However, the authors have very usefully suggested a pragmatic compromise between suggesting an optimal target blood pressure of 140 over 85 (or 140 over 80 mm Hg in diabetics), alongside 'audit standard' target blood pressure of up to 150 over 90 (140 over 85 mm Hg in diabetics). Since only 6% of the current hypertension population in England achieve target blood pressures below 140 over 90 mm Hg, suggesting an audit standard seems sensible, particularly since the clinical outcomes in the HOT study for patients maintaining blood pressure below 150 over 90 were only very slightly worse than for those under 140 over 85 mm Hg.
The latter sections in the guidelines provide substantive advice about the importance of targeting antihypertensive and associated treatments in higher risk groups. Thus, they cover the use of statins (in secondary 9 or primary 10 prevention), the treatment of elderly hypertensives, and the treatment of patients with diabetes, renal disease and pregnancy. These sections are non-controversial in their recommendations.
Perhaps the most disappointing section of the guidelines relates to choice of antihypertensive drugs. As has already been pointed out by Furberg et al 11 in an editorial accompanying the summary of the new guidelines, the authors can be criticised for moving away somewhat from the evidence-based rigor shown elsewhere in the guidelines in this section. It would have been helpful had the authors chosen to grade their recommendations for this treatment section against the North of England group criteria 12 used in the rest of the paper, rather than use the table headings of 'compelling' and 'possible' indications and contra-indications to various classes of antihypertensives.
The authors are also more conservative than some in their recommendations for the co-administration of aspirin. Use of 75 mg of aspirin in secondary prevention is non-controversial. However in primary prevention they suggest limiting co-administration to patients over the age of 50 with either target organ damage, or a 10-year CHD risk greater than 15%, or type 2 diabetes plus adequate blood pressure control to under 150 over 90 mm Hg. This seems intuitively appropriate, given that total mortality was similar between aspirin and placebo in both the thrombosis prevention trial 13 and the HOT trial, largely because the number of clinically significant bleeding episodes caused by aspirin were similar to the number of cardiovascular events prevented.
In summary, these new BHS guidelines represent a substantial challenge to established practice. I was not overly concerned about the criticisms, which could be levied at the guidelines with regard to treatment recommendations, since these are most likely to be substantially influenced by local drug formularies anyway. Such concerns should not obscure the principal strength of the guidelines in making definitive and evidence-based recommendations on which classes of patients should be targeted for treatment, in what order of priority, and when associated risk should also be treated. At a time when 60% of patients on the old disease threshold remain undiagnosed and only 30% of patients on the old treatment targets remain controlled, the significant lowering of both thresholds and targets present huge challenges for those providing health care.
These guidelines, though detailed and long, make important recommendations on how practitioners need to respond to the challenge of hypertension. I only hope that the full text therefore does become essential reading for the main drivers for hypertensive management either in hospital or primary care settings. It will be these clinical leads responsibility to translate and summarise these recommendations into local recommendations, summary guidelines, or clinical practicals that implement the recommendations at a practice level. The final ingredient of monitoring the recommendations against ongoing clinical audit is the final essential ingredient.
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